<DOC>
	<DOCNO>NCT02611492</DOCNO>
	<brief_summary>The Primary objective ass non-inferiority experimental arm ( arm B ) compare control arm ( arm A ) term Major Molecular Response ( MMolR ) 4th cycle ( MRD4 ) patient age 18-59 year old de novo Philadelphia positive ( Ph+ ) acute lymphoblastic leukemia ( ALL )</brief_summary>
	<brief_title>A Phase III Randomized Trial Reduction Chemotherapy Philadelphia Chromosome-positive ALL Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patient 1 . Whose blood bone marrow exploration complete steroid prephase 2 . Aged 1859 year old newlydiagnosed non previously treat Ph+ ALL accord WHO 2008 criterion ( confirm diagnosis Philadelphia chromosome define reciprocal translocation chromosome 9 22 , ( 9 ; 22 ) and/or presence BCRABL molecular maker ) 3 . With ≥ 20 % bone marrow blast 4 . With Eastern Cooperative Oncology Group ( ECOG ) Performans Status ≤ 3 5 . With without central nervous system ( CNS ) testis involvement 6 . Without evolve cancer ( except basal cell carcinoma skin `` situ '' carcinoma cervix ) chemo radiotherapy finish least since 6 month . 7 . Having receive previous treatment hematological disease ( include IT injection ) 8 . Having sign write informed consent 9 . With efficient contraception woman childbearing age ( exclude estrogen IUD ) 10 . With health insurance coverage 11. Who receive ( receive ) recommend steroid prephase . Note 1 : Secondary ALL ( antecedent chemo radiotherapy ) include Note 2 : In case high vascular risk ( see section `` study management '' ) patient able receive nilotinib unless ultra sound Doppler neck lower limb perform prephase treatment validate medical coordinator protocol via secretariat . Patient : 1 . Previously treat Tyrosine Kinase Inhibitor ( TKI ) 2 . With another active malignancy 3 . With general visceral contraindication intensive therapy ( except consider related ALL ) : 1 . Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal range ( ULN ) 2 . Total bilirubin &gt; 1.5 x ULN 3 . Creatinine &gt; 1.5 x ULN creatinine clearance &lt; 50 mL/mn 4 . Serum amylase lipase &gt; 1.5 x ULN antecedent acute pancreatitis 4 . With heart failure , include least one follow criterion : 1 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % low normal threshold , determine ECG heart failure ( NYHA grade III IV ) 2 . Impossibility measure QT interval ECG 3 . Complete leave bundle branch block 4 . Pacemaker 5 . Congenital long QT syndrome know familial antecedent long QT syndrome 6 . Antecedents current ventricular atrial tachyarrhythmia , clinically significant 7 . Baseline bradycardia ( &lt; 50 bpm ) clinically significant 8 . Corrected QT interval ( QTc ) &gt; 450 msec establish mean 3 baseline ECG 9 . Antecedents myocardial infarct past 6 month 10 . Instable angor within past 12 month 11 . Any heart condition clinically significant ( i.e . congestive heart failure , uncontrolled hypertension ) 5 . Active uncontrolled infection , concurrent disease deem interfere conduct study judge investigator 6 . Severe evolve infection , know HIV Human TLymphotropic Virus type I ( HTLV1 ) seropositivity , active infection hepatitis B C virus 7 . Pregnant ( betaHCG ) nursing woman 8 . Women childbearing potential willing use effective form contraception participation study least three month thereafter . Patient willing ensure beget child participation study least three month thereafter . 9 . Having receive investigational treatment participation another trial within 30 day prior enter study . 10 . Not able bear procedure frequency visit plan trial . 11 . Unable consent , tutelage curator , judiciary safeguard</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>